Madrigal Pharmaceuticals Inc (MDGL)
302.67
-12.48
(-3.96%)
USD |
NASDAQ |
Nov 14, 16:00
303.04
+0.37
(+0.12%)
After-Hours: 20:00
Madrigal Pharmaceuticals Free Cash Flow: -438.32M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -438.32M |
| June 30, 2024 | -455.82M |
| March 31, 2024 | -391.12M |
| December 31, 2023 | -325.71M |
| September 30, 2023 | -303.28M |
| June 30, 2023 | -277.13M |
| March 31, 2023 | -259.21M |
| December 31, 2022 | -225.07M |
| September 30, 2022 | -214.69M |
| June 30, 2022 | -201.20M |
| March 31, 2022 | -190.62M |
| December 31, 2021 | -184.13M |
| September 30, 2021 | -190.92M |
| June 30, 2021 | -193.17M |
| March 31, 2021 | -170.55M |
| December 31, 2020 | -157.90M |
| September 30, 2020 | -115.35M |
| June 30, 2020 | -78.82M |
| March 31, 2020 | -66.10M |
| December 31, 2019 | -41.80M |
| September 30, 2019 | -35.65M |
| June 30, 2019 | -29.58M |
| March 31, 2019 | -23.40M |
| December 31, 2018 | -25.53M |
| September 30, 2018 | -25.20M |
| Date | Value |
|---|---|
| June 30, 2018 | -24.90M |
| March 31, 2018 | -27.31M |
| December 31, 2017 | -22.44M |
| September 30, 2017 | -21.78M |
| June 30, 2017 | -26.07M |
| March 31, 2017 | -20.95M |
| December 31, 2016 | -17.61M |
| September 30, 2016 | -13.43M |
| June 30, 2016 | 30.31M |
| March 31, 2016 | 15.20M |
| December 31, 2015 | -3.142M |
| September 30, 2015 | -21.32M |
| June 30, 2015 | -74.41M |
| March 31, 2015 | -77.55M |
| December 31, 2014 | -79.07M |
| September 30, 2014 | -78.57M |
| June 30, 2014 | -76.57M |
| March 31, 2014 | -75.98M |
| December 31, 2013 | -78.18M |
| September 30, 2013 | -72.02M |
| June 30, 2013 | -68.88M |
| March 31, 2013 | -61.73M |
| December 31, 2012 | -54.64M |
| September 30, 2012 | -52.90M |
| June 30, 2012 | -51.51M |
Free Cash Flow Range, Past 5 Years
-455.82M
Minimum
Jun 2024
-41.80M
Maximum
Dec 2019
-224.04M
Average
-197.18M
Median
Free Cash Flow Benchmarks
| ADMA Biologics Inc | 78.82M |
| 89bio Inc | -280.54M |
| Corcept Therapeutics Inc | 142.60M |
| Sarepta Therapeutics Inc | -480.40M |
| Matinas BioPharma Holdings Inc | -17.87M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -66.98M |
| Cash from Investing (Quarterly) | -202.39M |
| Cash from Financing (Quarterly) | 7.462M |
| Free Cash Flow Per Share (Quarterly) | -3.116 |
| Free Cash Flow to Equity (Quarterly) | -68.24M |
| Free Cash Flow Yield | -6.99% |